Anurag Relan - Pharming Group Chief Officer
| PHAR Stock | USD 7.65 0.12 1.59% |
Insider
Anurag Relan is Chief Officer of Pharming Group NV
| Age | 52 |
| Address | Darwinweg 24, Leiden, Netherlands, 2333 CR |
| Phone | 31 71 524 7400 |
| Web | https://www.pharming.com |
Pharming Group Management Efficiency
The company has return on total asset (ROA) of (0.0138) % which means that it has lost $0.0138 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0818) %, meaning that it created substantial loss on money invested by shareholders. Pharming Group's management efficiency ratios could be used to measure how well Pharming Group manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Tangible Assets is likely to drop to -0.03. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Pharming Group's Asset Turnover is relatively stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Francis Conway | Larimar Therapeutics | N/A | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| , MBA | Molecular Partners AG | 51 | |
| David Elmaleh | PureTech Health PLC | 76 | |
| Luigi MD | Genenta Science SpA | 65 | |
| Gary MD | Verrica Pharmaceuticals | 47 | |
| Tim Obara | Genenta Science SpA | N/A | |
| Andy Meyer | Janux Therapeutics | 40 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Bennett MD | PureTech Health PLC | 84 | |
| James JD | Eliem Therapeutics | 58 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| LLM JD | Rezolute | 63 | |
| James Goding | Opthea | N/A | |
| CPA CPA | Opthea | 63 | |
| CFA CPA | Janux Therapeutics | 45 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Wayne MD | Janux Therapeutics | 63 | |
| Michael Gerometta | Opthea | 59 | |
Management Performance
| Return On Equity | -0.0818 | ||||
| Return On Asset | -0.0138 |
Pharming Group NV Leadership Team
Elected by the shareholders, the Pharming Group's board of directors comprises two types of representatives: Pharming Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharming. The board's role is to monitor Pharming Group's management team and ensure that shareholders' interests are well served. Pharming Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharming Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bruno Giannetti, Consultant | ||
| MD MBA, CEO President | ||
| Susanne Embleton, Investor Manager | ||
| Jeroen Wakkerman, Chief Officer | ||
| Ruud Outersterp, Chief Officer | ||
| Stephen Toor, Chief Americas | ||
| Anurag Relan, Chief Officer | ||
| MBA MD, CEO Pres | ||
| Alexander MBA, Chief Officer | ||
| Mireille MSc, Chief Officer | ||
| Daniela Hanovana, Chief Officer | ||
| MPH MD, Chief Officer |
Pharming Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharming Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0818 | ||||
| Return On Asset | -0.0138 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 463.77 M | ||||
| Shares Outstanding | 67.84 M | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 9.62 K | ||||
| Price To Earning | 41.53 X | ||||
| Price To Book | 2.26 X |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.